|
|
Vaccine Detail
|
ALVAC-CEA (6D)-B7.1 Vaccine |
| Vaccine Information |
- Vaccine Name: ALVAC-CEA (6D)-B7.1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007575
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: CD80, CEA
- CD80
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- CEACAM5 (CEA)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-CEA (6D)-B7.1 vaccine expresses both a highly immunogenic analogue (6D) of the immunodominant epitope of carcinoembryonic antigen (CEA) and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28. This agent was designed to stimulate host immune responses against tumor cells that express CEA. (NCI04) (NCIT_C29982).
|
| Host Response |
|
|
| References |
NCIT_C29982: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29982]
|
|
